We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

131 hedge funds and large institutions have $652M invested in Sciclone Pharmaceuticals Inc in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 42 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

206% more capital invested

Capital invested by funds: $213M → $652M (+$439M)

13% more funds holding

Funds holding: 116131 (+15)

12% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

35% less call options, than puts

Call options by funds: $608K | Put options by funds: $939K

Holders
131
Holders Change
+15
Holders Change %
+12.93%
% of All Funds
3.49%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
47
Reduced
42
Closed
8
Calls
$608K
Puts
$939K
Net Calls
-$331K
Net Calls Change
-$168K
Name Holding Trade Value Shares
Change
Change in
Stake
SGH
101
Schonfeld Group Holdings
New York
$165K -$80.9K -10,000 -35%
B
102
Barings
North Carolina
$155K
Cambridge Investment Research Advisors
103
Cambridge Investment Research Advisors
Iowa
$151K +$8.09K +1,000 +6%
TI
104
Trexquant Investment
Connecticut
$147K +$136K +16,800 New
Barclays
105
Barclays
United Kingdom
$141K +$80.8K +9,976 +130%
PAM
106
Panagora Asset Management
Massachusetts
$128K -$118K -14,602 -50%
Principal Financial Group
107
Principal Financial Group
Iowa
$124K -$35.6K -4,393 -24%
DC
108
Deere & Company
Illinois
$114K -$1.41M -174,437 -93%
Los Angeles Capital Management
109
Los Angeles Capital Management
California
$103K +$5.06K +625 +6%
RCM
110
Rotella Capital Management
Washington
$91K -$78.5K -9,700 -48%
SG Americas Securities
111
SG Americas Securities
New York
$88K +$81K +10,008 New
Legal & General Group
112
Legal & General Group
United Kingdom
$80K -$4.96K -613 -6%
SGAM
113
Smith Group Asset Management
Texas
$64K
UBS Group
114
UBS Group
Switzerland
$64K +$58.5K +7,231 New
TRCT
115
Tower Research Capital (TRC)
New York
$56K +$51.7K +6,392 New
RA
116
Royce & Associates
New York
$44K
FQ
117
First Quadrant
California
$39K -$299K -37,000 -89%
MOACM
118
Mutual of America Capital Management
New York
$39K +$35.7K +4,415 New
Simplex Trading
119
Simplex Trading
Illinois
$34K +$31.5K +3,894 New
FMT
120
First Mercantile Trust
Tennessee
$30K +$27.6K +3,413 New
BlackRock
121
BlackRock
New York
$19K
Royal Bank of Canada
122
Royal Bank of Canada
Ontario, Canada
$16K -$1.62K -200 -10%
Teacher Retirement System of Texas
123
Teacher Retirement System of Texas
Texas
$12K -$2.28K -282 -17%
Creative Planning
124
Creative Planning
Kansas
$7K +$1.23K +152 +22%
SEI Investments
125
SEI Investments
Pennsylvania
$7K +$5.51K +681 New

SCLN Hedge Fund Activity: Q4 2014 in Review

131 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q4 2014, worth a combined $652M — up 206% from $213M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SCLN positions and 8 closed out — a net gain of 17 holders — while 47 added to existing stakes and 42 trimmed.

The largest buyer was McKinley Capital Management, opening a new position worth an estimated $6.86M. The largest seller was LSV Asset Management, cutting an estimated $4.19M.

  • 131 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q4 2014, up from 116 in Q3 2014.
  • Funds reported $652M of Sciclone Pharmaceuticals Inc stock for Q4 2014, up 206% quarter-over-quarter.
  • 25 funds opened new Sciclone Pharmaceuticals Inc positions in Q4 2014 and 8 closed out, a net change of +17 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q4 2014 was McKinley Capital Management, an estimated $6.86M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q4 2014 was LSV Asset Management, an estimated $4.19M sold.

Based on aggregated 13F filings for Q4 2014.